Tacrolimus induction followed by maintenance monotherapy is useful in selected patients with moderate-to-severe ulcerative colitis refractory to prior treatment

Digestive and Liver Disease

Volumn 46, Issue 10, 2014, Pages 875-880

  Boschetti, Gilles ^a,b   Nancey, Stéphane ^a,b   Moussata, Driffa ^b   Stefanescu, Carmen ^c   Roblin, Xavier ^d   Chauvenet, Marion ^b   Stroeymeyt, Karine ^b   Bouhnik, Yoram ^c   Flourié, Bernard ^a,b  

^a CENTRE INTERNATIONAL DE RECHERCHE EN INFECTIOLOGIE   (France)

^b CENTRE HOSPITALIER LYON SUD   (France)

^c BEAUJON HOSPITAL   (France)

^d UNIVERSITÉ JEAN MONNET   (France)

Author keywords

Refractory; Tacrolimus; Treatment; Ulcerative colitis

Indexed keywords

TACROLIMUS; IMMUNOSUPPRESSIVE AGENT;

ADULT; ARTICLE; CLINICAL ARTICLE; DISEASE SEVERITY; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEMALE; FINGER TREMOR; HEADACHE; HUMAN; HYPERTENSION; HYPOMAGNESEMIA; KIDNEY DISEASE; MAINTENANCE THERAPY; MALE; MIDDLE AGED; MONOTHERAPY; NAUSEA; PRIMARY SCLEROSING CHOLANGITIS; PRIORITY JOURNAL; REMISSION; SPONDYLOARTHROPATHY; THROMBOTIC THROMBOCYTOPENIC PURPURA; TREATMENT OUTCOME; TREMOR; ULCERATIVE COLITIS; URINARY TRACT INFECTION; VEIN THROMBOSIS; YOUNG ADULT; CLINICAL TRIAL; COLITIS, ULCERATIVE; DRUG ADMINISTRATION; EVALUATION STUDY; INDUCTION CHEMOTHERAPY; MAINTENANCE CHEMOTHERAPY; MULTICENTER STUDY; ORAL DRUG ADMINISTRATION; PATIENT SELECTION; RETROSPECTIVE STUDY; SEVERITY OF ILLNESS INDEX;

ADMINISTRATION, ORAL; ADULT; COLITIS, ULCERATIVE; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INDUCTION CHEMOTHERAPY; MAINTENANCE CHEMOTHERAPY; MALE; MIDDLE AGED; PATIENT SELECTION; RETROSPECTIVE STUDIES; SEVERITY OF ILLNESS INDEX; TACROLIMUS; TREATMENT OUTCOME;

EID: 84922225490     PISSN: 15908658     EISSN: 18783562     Source Type: Journal    
DOI: 10.1016/j.dld.2014.06.005     Document Type: Article

References (30)

1. Lichtiger S., Present D.H., Kornbluth A., et al. Cyclosporine in severe ulcerative colitis refractory to steroid therapy. New England Journal of Medicine 1994, 330:1841-1845.
2. Actis G.C., Volpes R., Rizetto M. Oral microemulsion cyclosporin to reduce steroids rapidly in chronic active ulcerative colitis. European Journal of Gastroenterology and Hepatology 1999, 11:905-908.
3. Moussata D., Nancey S., Flourie B., et al. Chronic active ulcerative colitis: efficacy of intravenous followed by oral cyclosporine combined with azathioprine. Presse Medicale 2004, 33:590-594.
4. Kino T., Hatanaka H., Miyata S., et al. FK-506, a novel immunosuppressant isolated from a Streptomyces II. Immunosuppressive effect of FK-506 in vitro. Journal of Antibiotics 1987, 40:1256-1265.
5. Webster A., Woodroffe R.C., Taylor R.S., et al. Tacrolimus versus cyclosporin as primary immunosuppression for kidney transplant recipients. CDS Review 2005, 4:CD003961.
6. McAlister V.C., Haddad E., Renouf E., et al. Cyclosporin versus tacrolimus as primary immunosuppressant after liver transplantation: a meta-analysis. American Journal of Transplantation 2006, 6:1578-1585.
7. Okada Y., Maeda N., Takakura S., et al. Preventive and therapeutic effects of tacrolimus in an interleukine-10-deficient mouse model of colitis. Inflammation Research 2011, 60:1049-1059.
8. Hoshino H., Goto H., Sugiyama S., et al. Effects of FK506 on an experimental model of colitis in rats. Alimentary Pharmacology and Therapeutics 1995, 9:301-307.
9. Sandborn W.J., Present D.H., Isaacs K.L., et al. Tacrolimus for the treatment of fistulas in patients with Crohn's disease: a randomized, placebo-controlled trial. Gastroenterology 2003, 125:380-388.
10. Gerich M.E., Pardi D.S., Bruining D.H., et al. Tacrolimus salvage in anti-tumor necrosis factor antibody treatment-refractory Crohn's disease. Inflammatory Bowel Diseases 2013, 19:1107-1111.
11. Fellermann K., Tanko Z., Herrlinger K.R., et al. Response of refractory colitis to intravenous or oral tacrolimus (FK506). Inflammatory Bowel Diseases 2002, 8:317-324.
12. Baumgart D.C., Wiedenmann B., Dignass A.U. Rescue therapy with tacrolimus is effective in patients with severe and refractory inflammatory bowel disease. Alimentary Pharmacology and Therapeutics 2003, 17:1273-1281.
13. Högenauer C., Wenzl H.H., Hinterleitner T.A., et al. Effect of oral tacrolimus (FK 506) on steroid-refractory moderate/severe ulcerative colitis. Alimentary Pharmacology and Therapeutics 2003, 18:415-423.
14. Baumgart D.C., Pintoffl J.P., Sturm A., et al. Tacrolimus is safe and effective in patients with severe steroid-refractory or steroid-dependent inflammatory bowel disease - a long-term follow-up. American Journal of Gastroenterology 2006, 101:1048-1056.
15. Benson A., Barrett T., Sparberg M., et al. Efficacy and safety of tacrolimus in refractory ulcerative colitis and Crohn's disease: a single-center experience. Inflammatory Bowel Diseases 2008, 14:7-12.
16. Schmidt K.J., Herrlinger K.R., Emmrich J., et al. Short-term efficacy of tacrolimus in steroid-refractory ulcerative colitis - experience in 130 patients. Alimentary Pharmacology and Therapeutics 2013, 37:129-136.
17. Bousvaros A., Kirchner B.S., Werlin S.L., et al. Oral tacrolimus treatment of fulminant colitis in children. Journal of Pediatrics 2000, 137:794-799.
18. Ng S.C., Arebi N., Kamm M.A. Medium-term results of oral tacrolimus treatment in refractory inflammatory bowel disease. Inflammatory Bowel Diseases 2007, 13:129-134.
19. Ogata H., Matsui T., Nakamura M., et al. A randomised dose finding study of oral tacrolimus (FK506) therapy in refractory ulcerative colitis. Gut 2006, 55:1255-1262.
20. Ogata H., Kato J., Hirai F., et al. Double-blind, placebo-controlled trial of oral tacrolimus (FK506) in the management of hospitalized patients with steroid-refractory ulcerative colitis. Inflammatory Bowel Diseases 2012, 18:803-808.
21. Watson S., Pensabene L., Mitchell P., et al. Outcomes and adverse events in children and young adults undergoing tacrolimus therapy for steroid-refractory colitis. Inflammatory Bowel Diseases 2011, 17:22-29.
22. Naganuma M., Fujii T., Watanabe M. The use of traditional and newer calcineurin inhibitors in inflammatory bowel disease. Journal of Gastroenterology 2011, 46:129-137.
23. Lennard-Jones J.E., Shivananda S. Clinical uniformity of inflammatory bowel disease at presentation and during the first year of disease in the north and south of Europe EC-IBD Study Group. European Journal of Gastroenterology and Hepatology 1997, 9:353-359.
24. Sutherland L.R., Martin F., Greer S., et al. 5-Aminosalicylic acid enema in the treatment of distal ulcerative colitis, proctosigmoiditis, and proctitis. Gastroenterology 1987, 92:1894-1898.
25. Yamamoto S., Nakase H., Mikami S., et al. Long-term effect of tacrolimus therapy in patients with refractory ulcerative colitis. Alimentary Pharmacology and Therapeutics 2008, 28:589-597.
26. Yamamoto S., Nakase W.H., Matsuura M., et al. Tacrolimus therapy as an alternative to thiopurines for maintaining remission in patients with refractory ulcerative colitis. Journal of Clinical Gastroenterology 2011, 45:526-530.
27. Okafor P.N., Nunes D.P., Farraye F.A. Pneumocystis jiroveci pneumonia in inflammatory bowel disease: when should prophylaxis be considered?. Inflammatory Bowel Diseases 2013, 19:1764-1771.
28. Ziring D.A., Wu S.S., Mow W.S., et al. Oral tacrolimus for steroid-dependent and steroid-resistant ulcerative colitis in children. Journal of Pediatric Gastroenterology and Nutrition 2007, 45:306-311.
29. Herrlinger K.R., Koc H., Winter S., et al. ABCB1 single-nucleotide polymorphisms determine tacrolimus response in patients with ulcerative colitis. Clinical Pharmacology and Therapeutics 2011, 89:422-428.
30. Fujii T., Naganuma M., Saito E., et al. Intravenous tacrolimus therapy can rapidly induce remission in refractory ulcerative colitis. Gastroenterology 2012, Abstract Sa1907.